RenBio

RenBio is happy to announce the publication of a recent article in Pharmaceutics, “Enhancing In Vivo Electroporation Efficiency Through Hyaluronidase: Insights into Plasmid Distribution and Optimization Strategies." Led by Senior Research Engineer, Debnath Maji, we take a look into the promising realm of non-viral plasmid DNA delivery through intramuscular electroporation (EP) and highlight the role of hyaluronidase in enhancing transfection efficiency. Hyaluronidase has the ability to promote uniform distribution of plasmid DNA within skeletal muscle, and by leveraging bioimpedance measurements, we decipher changes induced by hyaluronidase treatment, allowing for further optimization of  EP electrical parameters. This work underscores hyaluronidase's potential in augmenting in vivo EP efficacy and offers a roadmap for tailored EP strategies. Read the full article here, https://lnkd.in/ezUETurk! 

RenBio is seeking a Research Scientist I/II to join our team! Are you interested in cutting-edge technologies and want to change how we fight infectious diseases? If so, this position might be perfect for you. Apply now at https://lnkd.in/g_AG4KfK or share with your network!

Exciting Opportunity at RenBio! Join our innovative team as a Research Associate. We're looking for a highly motivated and goal-oriented individual to contribute to our dynamic and collaborative research environment. If you're passionate about pushing scientific boundaries, fostering innovation, and making a significant impact, we want to hear from you! Apply now at https://lnkd.in/epM_ZQQm or share with your network!

RenBio is thrilled to announce that our most recent review , "Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases,” is out (https://lnkd.in/e8usgcgs)! Led by Research Associate Carleigh Sussman, it provides a comprehensive overview of gene therapy's evolution and its pivotal role in modern medicine. It delves into the promise of DNA-based medicines, particularly in managing chronic conditions more effectively. The review explores two key DNA-based gene therapies: adeno-associated virus (AAV)-based gene therapy and plasmid DNA (pDNA)-based gene therapy. It discusses how both have shown immense potential in clinical trials, offering robust and durable expression of therapeutic genes with fewer treatments compared to traditional approaches. Moreover, this review sheds light on the use of electroporation (EP) as a method for pDNA delivery. EP has emerged as a promising technique to enhance the efficacy and durability of pDNA-based therapies, paving the way for more efficient treatment strategies for chronic diseases.  #GeneTherapy #ChronicDiseases #ResearchInnovation

Thrilled to announce that Dr. Rachel Liberatore, PhD and Dr. Linda Sasset are representing RenBio at the ASGCT 27th Annual Meeting in Baltimore! Join us as Dr. Sasset presents her abstract titled "Next-Generation DNA-Based Delivery of Therapeutic Proteins Using MYO Technology: Preclinical Results on Incretins Receptor Agonists" tomorrow at 12:00 PM. Don't miss out on poster #1741! #ASGCT2024 #Biotechnology

RenBio's Dr. Rachel Liberatore, PhD will be at 'AntibodyTherapeutics Xchange 2024' in Philadelphia tomorrow, March 25th through March 27th. Join Dr. Liberatore for a round table discussion on "Novel Delivery Modes for Biologics." We'll explore improving PK, addressing cold chain requirements, and the burden of medical devices. Don't miss out! #AntibodyTherapeutics #BiologicsDelivery #RenBio #Biotechnology https://lnkd.in/eUqXWGMe

Looking forward to a great meeting.

Dr. Rachel Liberatore, PhD will be representing our team at the BIO CEO & Investor Conference in New York today and tomorrow! This is a fantastic opportunity for Renbio to showcase our innovative work in the biotech industry and connect with other leaders and investors in the field. If you're attending, we'd love the opportunity to connect and share insights! Stay tuned for updates on our latest developments. #Renbio #BIOCEOInvestorConference #BiotechInnovation https://bcic.bio.org/about

Exciting Opportunity at RenBio! Join our dynamic team as a Research Scientist I/II and contribute to groundbreaking advancements in biotechnology, medical device development, and therapeutic proteins. We're seeking a highly motivated PhD-level scientist to play a pivotal role in our innovative projects. Qualifications: *Required* - PhD in cell or molecular biology, pharmacology, immunology, or related field - 2 years of industry drug development experience or 3 years of postdoctoral experience - Hands-on experience in vivo models and molecular biology techniques - Knowledge of monoclonal antibody engineering - Excellent computer skills and communication abilities *Preferred* - Knowledge of virology and experience with biochemistry techniques - Proficiency with GraphPad Prism - Experience in medical device development If you're passionate about pushing scientific boundaries, fostering innovation, and making a real impact, we want to hear from you! Apply now at https://lnkd.in/eSyiiFCA or share with your network! #biotechnology #ResearchScientist #Innovation #JobOpportunity #RenBio

RenBio is thrilled to announce that our President & Chief Scientific Officer, Rachel Liberatore, PhD, will be representing us at the Biotech Showcase in San Francisco from January 8th to 10th! We're excited to connect with fellow industry leaders and innovators at the Biotech Showcase. Are you attending the Biotech Showcase? Make sure to connect with Dr. Liberatore to explore potential collaborations, discuss groundbreaking advancements, and learn more about RenBio's latest endeavors in the biotech realm. Stay tuned for updates from Dr. Liberatore as she dives into discussions and networking opportunities at the event. We can't wait to share insights and foster new connections! https://lnkd.in/etmiN9MA #RenBio #BiotechShowcase #InnovationInBiotech #BiotechCommunity  #Biotechnology